A Phase 3 interventional study of Vitamin D and Artificial tear in Dry Eye Syndromes and Hypovitaminosis D, sponsored by University of Faisalabad. Completed at 1 site in Pakistan. Open to participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2022-06-21.
Sponsored by University of Faisalabad · Phase 3, Interventional, and Treatment
Among 14 studies in Dry Eye Syndromes with a site in Pakistan — none open to participants now, 9 under way, none of them phase 3. Dry Eye Syndromes · Pakistan.
Among the 14 studies in Dry Eye Syndromes with a site in Pakistan, this one is the 3rd largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2021, is the only one in phase 3, and was the 4th registered.
1,366 studies on the registry are indexed under Dry Eye Syndromes; 207 are open to participants now.
Browse Dry Eye Syndromes studies →None of the 14 studies in Dry Eye Syndromes with a site in Pakistan is open now. The open studies under Dry Eye Syndromes, anywhere →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 20 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 108 is above the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 64 across the 11 interventional studies, 120 across the 3 observational. Of the 2 that completed or were terminated, 1 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 14 has an industry lead sponsor. The 4 most frequent:
University of Faisalabad is the lead sponsor of 87 studies on the registry; 28 are open to participants now.
University of Faisalabad has 3 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Dry Eye Syndromes with a site in Pakistan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Dry eye disease is multifactorial, ocular inflammatory condition causing irritation, stinging sensation, uneasiness and blurring. Non-Sjogren syndrome occurs due to absent or dysfunction of lacrimal gland. Fat soluble vitamin D act as an agent against inflammation and its deficiency may result in various inflammatory diseases including dry eye. Purpose of this study is evaluation of vitamin D3 supplementation role in treating non-Sjogren dry eye along with conventional treatment by using artificial tears in patients with hypovitaminosis D. A prospective study was conducted in Rural health center(RHC) Buchal Kalan on 108 patients presenting with non-Sjogren dry eyes and low serum vitamin D levels. Patients were subjected to the following examination; best corrected visual acuity (BCVA), slit-lamp examination, applanation tonometry, fundoscopy, tear breakup time (TBUT) after fluorescein staining, Schirmer tear test, numerical pain rating scale (NPRS) and ocular surface disease index (OSDI) score on day 0, 15, 30, 60 and 90. Vitamin D levels was assessed by electrochemiluminescence immunoassay (ECLIA) based analyzer. The sample was randomly divided into two groups by non-probability purposive sampling. Group 1 received only artificial tears 4times/day while group 2 were given oral vitamin D3 supplementation of 6000 international unit (IU) daily along with artificial tears. Impact of oral vitamin D3 supplementation on non-Sjogren dry eyes was assessed by comparing means of ocular parameters of both groups over different period of time by using Mann-Whitney Test and Friedman Test.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Receiving conventional dry eye treatment in the form of artificial tears four times per days for 90 days.
Drug: Artificial tear
Receiving vitamin d3 supplementation 6000IU per day along with artificial tears for 90 days.
Drug: Vitamin D · Drug: Artificial tear
New treatment option for dry eye patients with low serum vitamin D Level
Conventional dry eye treatment
Tear Breakup time in seconds
Improvement after vitamin D3 supplementation over a period of time
Time frame: 90 days
Schirmer test score in millimeters
Improvement after vitamin D3 supplementation over a period of time
Time frame: 90 days
Ocular surface disease index score in units
Change in both groups after treatment. Values ranges from 0 to 100. Higher score indicates worse condition.
Time frame: 90 days
Numerical Pain Rating Scale
Change in both groups after treatment. Values ranges from 0 to 10 wher 0 indicates no pain while 10 indicates worst pain
Time frame: 90 days
Plan to share: No — Plan to share results only due to confidentiality
No publications or documents are linked to this record.
Ran from Nov 2021 to primary completion in Mar 2022, 4 months.
Of 96 phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 15. This study's 4 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vitamin D
University of Faisalabad